Mean age, years (SD)a
|
45 (3)
|
45 (3)
|
45 (3)
|
0
|
0
|
Male sex (%)b
|
37%
|
32%
|
40%
|
−0.15
|
0.08
|
Baseline HbA1c
|
8.29
|
8.31
|
8.41
|
−0.02
|
0.07
|
Comorbidities, N (%)
|
Anemia
|
55(15%)
|
29 (11%)
|
232 (11%)
|
−0.11
|
−0.11
|
Angina
|
59 (16%)
|
28 (11%)
|
227 (11%)
|
−0.15
|
− 0.15
|
Anxiety
|
35 (10%)
|
39 (15%)
|
375 (17%)
|
0.15
|
0.21
|
Asthma
|
73 (20%)
|
48 (19%)
|
388 (18%)
|
−0.03
|
− 0.05
|
CAD
|
121 (34%)
|
60 (24%)
|
544 (25%)
|
−0.22
|
−0.20
|
CHF
|
49 (14%)
|
28 (11%)
|
251 (12%)
|
−1.46
|
−0.16
|
CKD
|
103 (29%)
|
56 (22%)
|
360 (17%)
|
−0.28
|
−0.52
|
COPD
|
56 (16%)
|
48 (19%)
|
393 (18%)
|
0.08
|
0.05
|
Cardiomyopathy
|
19 (5%)
|
9 (4%)
|
88 (4%)
|
−0.25
|
−0.25
|
Other CTD
|
21 (6%)
|
12 (5%)
|
67 (3%)
|
0.20
|
0.71
|
Depression
|
71 (20%)
|
65 (26%)
|
503 (23%)
|
0.26
|
0.14
|
DM retinopathy
|
64 (18%)
|
42 (17%)
|
29 (1%)
|
−0.06
|
−1.37
|
Hypertension
|
316 (88%)
|
217 (85%)
|
1807 (84%)
|
−0.03
|
−0.05
|
Hypothyroidism
|
112 (31%)
|
88 (35%)
|
671 (31%)
|
0.12
|
0.00
|
Dyslipidemia
|
312 (86%)
|
225 (89%)
|
1825 (85%)
|
0.03
|
−0.01
|
Inflammatory bowel disease
|
9 (2%)
|
12 (5%)
|
44 (2%)
|
0.90
|
0.00
|
Liver disease
|
88 (24%)
|
64 (25%)
|
408 (19%)
|
0.04
|
−0.24
|
Myocardial infarction
|
23 (6%)
|
8 (3%)
|
36 (2%)
|
−0.71
|
−1.00
|
Obesity
|
98 (27%)
|
72 (28%)
|
629 (29%)
|
0.04
|
0.07
|
Psoriasis
|
43 (12%)
|
81 (32%)
|
154 (7%)
|
0.84
|
−0.54
|
Baseline diabetes medications, N (%)
|
316 (88%)
|
232 (91%)
|
2144 (100%)
|
0.03
|
0.13
|
Baseline MTX, N (%)
|
–
|
128 (50%)
|
274 (13%)
|
n/a
|
n/a
|
Baseline TNFi, N (%)
|
36 (10%)
|
84 (33%)
|
214 (10%)
|
0.96
|
0.00
|
Baseline Steroidsc, N (%)
|
152 (42%)
|
100 (39%)
|
394 (18%)
|
−0.07
|
−0.75
|
Average baseline glucocorticoid dose, mean (SD)
|
6 (7)
|
6 (6)
|
5(7)
|
0
|
0.14
|
Duration btwn baseline and f/up HbA1c, mean # of days (SD)
|
241 (83)
|
237 (84)
|
201 (79)
|
0.05
|
−0.49
|
Duration btwn med start date and f/up HbA1c, mean # of days (SD)
|
173 (66)
|
166 (65)
|
168(66)
|
−0.11
|
−0.08
|